• June 2, 2020

Ampio Provides Update on COVID-19 Program - Odessa American: Business

e-Edition Subscribe

Ampio Provides Update on COVID-19 Program

Font Size:
Default font size
Larger font size

Posted: Friday, May 22, 2020 7:00 am

ENGLEWOOD, Colo., May 22, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").

Ampio has filed Investigative New Drug ("IND") applications for Ampion™ with the FDA and has maintained ongoing dialog with the FDA regarding the Company's development of treatment options which includes inhalation and intravenous applications for COVID-19 affected patients.

Years of extensive in-vitro studies on cell cultures have confirmed that the mechanism of action ("MOA") of Ampion may be suitable for the treatment of inflammatory conditions, such as acute respiratory distress syndrome ("ARDS") and the cytokine storm, associated with COVID-19. Many of these research related findings have been published in peer reviewed, scientific journals, which can be found on the Company's website.

About Ampio Pharmaceutical

Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2032 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act ("BPCIA").

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application ("BLA"), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact Dan Stokely, CFO Phone: (720) 437-6500 info@ampiopharma.com Ampio Pharmaceuticals, Inc. AMPE

View original content to download multimedia: http://www.prnewswire.com/news-releases/ampio-provides-update-on-covid-19-program-301064052.html

SOURCE Ampio Pharmaceuticals, Inc.

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Mostly Cloudy
Humidity: 67%
Winds: SSE at 12mph
Feels Like: 74°

Your Extended Forecast


High 89°/Low 67°
Times of sun and clouds. Highs in the upper 80s and lows in the upper 60s.


High 94°/Low 68°
Times of sun and clouds. Highs in the mid 90s and lows in the upper 60s.


High 98°/Low 69°
Abundant sunshine. Highs in the upper 90s and lows in the upper 60s.
Online Features

Pet Central


Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>



Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>



Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>



Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>

  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.